Dry Eye Syndrome Treatment Market Size, Trends, Share, Growth | Report 2022-2030
The global dry eye syndrome treatment market was valued at USD 5.11 billion in 2021 and it is predicted to surpass around USD 7.6 billion by 2030 with a CAGR of 4.51% from 2022 to 2030.
Report Highlights
The growth of the market is attributed to factors such as the increasing use of screens, the rising geriatric population, and a heightened prevalence of eye diseases.
The heightened use of devices with a screen, surging use of computers, and a decreased number of blinks are subsequently leading to the growth of evaporative dry eye syndrome globally. For instance, as per Frontiers Journal in 2021, when compared to pre-pandemic years, the use of screens has increased by 60–80% in adults during the COVID-19 pandemic. The exposure to the screen leads to a 66% decreased blinking rate, thus escalating the evaporation of tears and leading to dry eye disease.
Over-the-counter (OTC) products predominate the marketplace due to the extremely low acceptance of prescription products. For instance, only 10% of the diagnosed population is on prescription therapies, while 75% of the population has never tried prescription therapy. However, the number of patients diagnosed with dry eye syndrome accounts for 5-35% of overall ophthalmologist visits.
Moreover, existing products such as Xiidra and Restasis take months or weeks to demonstrate effects. In addition, as per eye consultants, these products have tolerability issues and a failure rate of as high as 50%. This depicts an unmet need in the market and is anticipated to create a lucrative opportunity for pipeline products expected to launch in the upcoming years. Moreover, regulations associated with the drugs further hamper the growth of the overall market. For instance, in 2020, Novartis had to voluntarily withdraw the use of Xiidra in Europe after regulators raised major objections to its use of xiidra.
Innovations and strategic initiatives by key players are driving the market. New product launch is a common strategy being used by the players. For instance, in October 2021, Tyrvaya (varenicline solution) nasal spray by Oyster Point Pharma was approved by the FDA as an alternative treatment approach.
Scope of The Report
| Report Coverage | Details |
| Market Size in 2021 | USD 5.11 billion |
| Revenue Forecast by 2030 | USD 7.6 billion |
| Growth rate from 2022 to 2030 | CAGR of 4.51% |
| Base Year | 2021 |
| Forecast Period | 2022 to 2030 |
| Segmentation | Type, drug, product, dosage form, sales channel, distribution channel, region |
| Companies Covered |
Novartis AG; AbbVie, Inc.; Sun Pharmaceutical Industries Ltd.; Santen Pharmaceutical Co., Ltd.; AFT Pharmaceuticals; Johnson & Johnson Services, Inc.; Otsuka Pharmaceutical Co., Ltd.; OASIS Medical.; Oyster Point Pharma, Inc., Bausch & Lomb |
Type Insights
Evaporative dry eye syndrome dominated the market in 2021 with a revenue share of over 80.04% owing to the high prevalence of the disease, which can be associated with factors such as an increase in screen time, reduced rate of blinking, and reduced tear formation due to age. The easy availability of products such as EvoTears targeted at the evaporative type of the disease makes access to treatment easier.
Aqueous dry eye syndrome occurs due to the inability of the lacrimal glands to produce tears. The chronic inflammation along with the thickened tear ducts can result in the accumulation of tears within the lacrimal gland, thus causing aqueous tear deficiency and dry eye. Treatment for aqueous dry eye syndrome includes artificial tears and medicines such as cyclosporine and punctal plugs.
Drug Insights
The Restasis drug segment accounted for the largest revenue share of over 25.08% in 2021 owing to its use in chronic dry eye symptoms. The drug is marketed by Allergan and is highly adopted across the population pertaining to very less side effects associated with the drug. Although the drug requires 3 to 6 months to start working on the condition, it is highly being used as a prescription drug with remarkable treatment results. The segment is expected to register a slow growth rate during the forecast period owing to the approval of generic Restasis from Mylan Pharmaceuticals Inc. by the FDA in February 2022.
Xiidra drug is anticipated to grow at a lucrative rate during the forecast period. The drug was approved by the U.S. FDA for the treatment of signs and symptoms of dry eye disease. The growth of xiidra is due to the high adoption of the drug. Moreover, it is the first medication in a new class of drugs, called lymphocyte function-associated antigen 1 antagonist for the treatment of the dry eye. Moreover, the drug is a leading product for dry eye commercially marketed by Novartis and approved in major regions across the world.
Product Insights
The cyclosporine segment accounted for the largest revenue share of over 60.11% in 2021 owing to the long-standing use of medications using cyclosporine as a basis. Its effectiveness for dry eye disease symptoms and clinical indicators has been demonstrated through research. As an inflammatory reaction that plays a part in illness, cyclosporine has been found to inhibit T-cell proliferation. FDA-approved medications for treating the symptoms of dry eye include Restasis and Cequa.
Topical corticosteroids are anticipated to grow at the fastest rate over the forecast period. The growth of the market is attributed to the quick action of corticosteroid drugs than immunomodulatory-based drugs. The U.S. FDA-approved Eysuvis launched in Jan 2021 is used for treating both signs and symptoms of dry eye disease.
Dosage Form Insights
The eye drops segment accounted for the largest revenue share of over 35.09% in 2021 owing to the ease of usage and administration, which leads to increased patient compliance with the treatment. However, this is a topical mode of administration, which makes the action of the product less sustained and the elimination of the product easy. The launch of products in this segment is common and the movement of players is high. For instance, in April 2021, Alcon announced the launch of its Systane eye drops with hydroboost technology for providing long-lasting relief to patients that apply eye drops over 4 times a day.
Eye solutions are anticipated to grow at the fastest rate owing to the presence of products such as Xiidra and Restasis. However, products such as ointments and gels are preferred for usage at night owing to their long-lasting effects, thereby making this segment lucrative for the key players. For instance, in December 2021, NTC Srl and I-MED announced a partnership for making 0.4% sodium hyaluronate ointment available in the U.S. market.
Sales Channel Insights
The OTC segment accounted for the largest revenue share of over 60.04% in 2021 owing to the ease of usage and purchase. The advent of the pandemic and an increasing number of people moving toward self-medication have compelled people to buy drugs over the counter. The availability of various eye drops that are easy to use is leading to the growth of the segment.
Prescription drugs are anticipated to grow at a lucrative rate over the forecast period. The growth of the market is attributed to the increasing prevalence of dry eye among the population. For instance, according to the American Academy of Ophthalmology, over the age of 50 years, 1.68 million men and 3.2 million women experience dry eye. However, out of a total number of patients diagnosed with dry eye syndrome, only 10% of the population is on prescription therapies, while 75% of the population has never tried prescription therapy.
Distribution Channel Insights
The retail pharmacies segment accounted for the largest revenue share of over 45.22% in 2021. This is attributed to the ease of access to retail pharmacies. Moreover, the presence of pharmacists to assist with dosages, customer services, and provision of consultations in some regions help the segment gain a competitive edge in the market.
The online pharmacies segment is projected to grow at the fastest rate over the forecast period due to a surge in the number of people buying products due to convenience. Furthermore, the pandemic has increased the adoption of online pharmacies due to restrictions on the movement of people. Moreover, the availability of better pricing in these online stores facilitates repeat purchases.
Regional Insights
North America accounted for the largest revenue share of over 35.4% in 2021. The presence of a wide target population, better access to healthcare, and a high rate of treatment adoption are anticipated to drive the market in this region. Moreover, the lucrative nature of the market attracts players in this region. For instance, in October 2019, Cequa was launched by Sun Pharmaceutical Industries Ltd. in the region.
Asia Pacific is estimated to be the fastest-growing segment over the forecast period due to improvements in overall healthcare infrastructure, rising prevalence of dry eye disease, and improved access to healthcare. In addition, the presence of key players in this region such as Otsuka Pharmaceuticals Co. Ltd. and Santen Pharmaceuticals is expected to drive the overall market.
Key Players
Market Segmentation
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Distribution Channel Procurement Analysis
4.3.2. Sales and Distribution Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Dry Eye Syndrome Treatment Market
5.1. COVID-19 Landscape: Dry Eye Syndrome Treatment Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Dry Eye Syndrome Treatment Market, By Type
8.1. Dry Eye Syndrome Treatment Market, by Type, 2022-2030
8.1.1. Evaporative Dry Eye Syndrome
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Aqueous Deficient Dry Eye Syndrome
8.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Dry Eye Syndrome Treatment Market, By Drug
9.1. Dry Eye Syndrome Treatment Market, by Drug, 2022-2030
9.1.1. Restasis
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Xiidra
9.1.2.1. Market Revenue and Forecast (2017-2030)
9.1.3. Cequa
9.1.3.1. Market Revenue and Forecast (2017-2030)
9.1.4. Eysuvis
9.1.4.1. Market Revenue and Forecast (2017-2030)
9.1.5. Tyrvaya
9.1.5.1. Market Revenue and Forecast (2017-2030)
9.1.6. Others
9.1.6.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Dry Eye Syndrome Treatment Market, By Product
10.1. Dry Eye Syndrome Treatment Market, by Product, 2022-2030
10.1.1. Cyclosporine
10.1.1.1. Market Revenue and Forecast (2017-2030)
10.1.2. Topical Corticosteroids
10.1.2.1. Market Revenue and Forecast (2017-2030)
10.1.3. Artificial Tears
10.1.3.1. Market Revenue and Forecast (2017-2030)
10.1.4. Punctal Plugs
10.1.4.1. Market Revenue and Forecast (2017-2030)
10.1.5. Oral Omega Supplements
10.1.5.1. Market Revenue and Forecast (2017-2030)
10.1.6. Others
10.1.6.1. Market Revenue and Forecast (2017-2030)
Chapter 11. Global Dry Eye Syndrome Treatment Market, By Dosage Form
11.1. Dry Eye Syndrome Treatment Market, by Dosage Form, 2022-2030
11.1.1. Gels
11.1.1.1. Market Revenue and Forecast (2017-2030)
11.1.2. Eye Solutions
11.1.2.1. Market Revenue and Forecast (2017-2030)
11.1.3. Capsules & Tablets
11.1.3.1. Market Revenue and Forecast (2017-2030)
11.1.4. Eye Drops
11.1.4.1. Market Revenue and Forecast (2017-2030)
11.1.5. Ointments
11.1.5.1. Market Revenue and Forecast (2017-2030)
Chapter 12. Global Dry Eye Syndrome Treatment Market, By Sales Channel
12.1. Dry Eye Syndrome Treatment Market, by Sales Channel, 2022-2030
12.1.1. Prescription
12.1.1.1. Market Revenue and Forecast (2017-2030)
12.1.2. OTC
12.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 13. Global Dry Eye Syndrome Treatment Market, By Distribution Channel
13.1. Dry Eye Syndrome Treatment Market, by Distribution Channel, 2022-2030
13.1.1. Hospital Pharmacies
13.1.1.1. Market Revenue and Forecast (2017-2030)
13.1.2. Retail Pharmacies
13.1.2.1. Market Revenue and Forecast (2017-2030)
13.1.3. Online Pharmacies
13.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 14. Global Dry Eye Syndrome Treatment Market, Regional Estimates and Trend Forecast
14.1. North America
14.1.1. Market Revenue and Forecast, by Type (2017-2030)
14.1.2. Market Revenue and Forecast, by Drug (2017-2030)
14.1.3. Market Revenue and Forecast, by Product (2017-2030)
14.1.4. Market Revenue and Forecast, by Dosage Form (2017-2030)
14.1.5. Market Revenue and Forecast, by Sales Channel (2017-2030)
14.1.6. Market Revenue and Forecast, by Distribution Channel (2017-2030)
14.1.7. U.S.
14.1.7.1. Market Revenue and Forecast, by Type (2017-2030)
14.1.7.2. Market Revenue and Forecast, by Drug (2017-2030)
14.1.7.3. Market Revenue and Forecast, by Product (2017-2030)
14.1.7.4. Market Revenue and Forecast, by Dosage Form (2017-2030)
14.1.8. Market Revenue and Forecast, by Sales Channel (2017-2030)
14.1.8.1. Market Revenue and Forecast, by Distribution Channel (2017-2030)
14.1.9. Rest of North America
14.1.9.1. Market Revenue and Forecast, by Type (2017-2030)
14.1.9.2. Market Revenue and Forecast, by Drug (2017-2030)
14.1.9.3. Market Revenue and Forecast, by Product (2017-2030)
14.1.9.4. Market Revenue and Forecast, by Dosage Form (2017-2030)
14.1.10. Market Revenue and Forecast, by Sales Channel (2017-2030)
14.1.11. Market Revenue and Forecast, by Distribution Channel (2017-2030)
14.1.11.1.
14.2. Europe
14.2.1. Market Revenue and Forecast, by Type (2017-2030)
14.2.2. Market Revenue and Forecast, by Drug (2017-2030)
14.2.3. Market Revenue and Forecast, by Product (2017-2030)
14.2.4. Market Revenue and Forecast, by Dosage Form (2017-2030)
14.2.5. Market Revenue and Forecast, by Sales Channel (2017-2030)
14.2.6. Market Revenue and Forecast, by Distribution Channel (2017-2030)
14.2.7.
14.2.8. UK
14.2.8.1. Market Revenue and Forecast, by Type (2017-2030)
14.2.8.2. Market Revenue and Forecast, by Drug (2017-2030)
14.2.8.3. Market Revenue and Forecast, by Product (2017-2030)
14.2.9. Market Revenue and Forecast, by Dosage Form (2017-2030)
14.2.10. Market Revenue and Forecast, by Sales Channel (2017-2030)
14.2.10.1. Market Revenue and Forecast, by Distribution Channel (2017-2030)
14.2.11. Germany
14.2.11.1. Market Revenue and Forecast, by Type (2017-2030)
14.2.11.2. Market Revenue and Forecast, by Drug (2017-2030)
14.2.11.3. Market Revenue and Forecast, by Product (2017-2030)
14.2.12. Market Revenue and Forecast, by Dosage Form (2017-2030)
14.2.13. Market Revenue and Forecast, by Sales Channel (2017-2030)
14.2.14. Market Revenue and Forecast, by Distribution Channel (2017-2030)
14.2.14.1.
14.2.15. France
14.2.15.1. Market Revenue and Forecast, by Type (2017-2030)
14.2.15.2. Market Revenue and Forecast, by Drug (2017-2030)
14.2.15.3. Market Revenue and Forecast, by Product (2017-2030)
14.2.15.4. Market Revenue and Forecast, by Dosage Form (2017-2030)
14.2.16. Market Revenue and Forecast, by Sales Channel (2017-2030)
14.2.16.1. Market Revenue and Forecast, by Distribution Channel (2017-2030)
14.2.17. Rest of Europe
14.2.17.1. Market Revenue and Forecast, by Type (2017-2030)
14.2.17.2. Market Revenue and Forecast, by Drug (2017-2030)
14.2.17.3. Market Revenue and Forecast, by Product (2017-2030)
14.2.17.4. Market Revenue and Forecast, by Dosage Form (2017-2030)
14.2.18. Market Revenue and Forecast, by Sales Channel (2017-2030)
14.2.18.1. Market Revenue and Forecast, by Distribution Channel (2017-2030)
14.3. APAC
14.3.1. Market Revenue and Forecast, by Type (2017-2030)
14.3.2. Market Revenue and Forecast, by Drug (2017-2030)
14.3.3. Market Revenue and Forecast, by Product (2017-2030)
14.3.4. Market Revenue and Forecast, by Dosage Form (2017-2030)
14.3.5. Market Revenue and Forecast, by Sales Channel (2017-2030)
14.3.6. Market Revenue and Forecast, by Distribution Channel (2017-2030)
14.3.7. India
14.3.7.1. Market Revenue and Forecast, by Type (2017-2030)
14.3.7.2. Market Revenue and Forecast, by Drug (2017-2030)
14.3.7.3. Market Revenue and Forecast, by Product (2017-2030)
14.3.7.4. Market Revenue and Forecast, by Dosage Form (2017-2030)
14.3.8. Market Revenue and Forecast, by Sales Channel (2017-2030)
14.3.9. Market Revenue and Forecast, by Distribution Channel (2017-2030)
14.3.10. China
14.3.10.1. Market Revenue and Forecast, by Type (2017-2030)
14.3.10.2. Market Revenue and Forecast, by Drug (2017-2030)
14.3.10.3. Market Revenue and Forecast, by Product (2017-2030)
14.3.10.4. Market Revenue and Forecast, by Dosage Form (2017-2030)
14.3.11. Market Revenue and Forecast, by Sales Channel (2017-2030)
14.3.11.1. Market Revenue and Forecast, by Distribution Channel (2017-2030)
14.3.12. Japan
14.3.12.1. Market Revenue and Forecast, by Type (2017-2030)
14.3.12.2. Market Revenue and Forecast, by Drug (2017-2030)
14.3.12.3. Market Revenue and Forecast, by Product (2017-2030)
14.3.12.4. Market Revenue and Forecast, by Dosage Form (2017-2030)
14.3.12.5. Market Revenue and Forecast, by Sales Channel (2017-2030)
14.3.12.6. Market Revenue and Forecast, by Distribution Channel (2017-2030)
14.3.13. Rest of APAC
14.3.13.1. Market Revenue and Forecast, by Type (2017-2030)
14.3.13.2. Market Revenue and Forecast, by Drug (2017-2030)
14.3.13.3. Market Revenue and Forecast, by Product (2017-2030)
14.3.13.4. Market Revenue and Forecast, by Dosage Form (2017-2030)
14.3.13.5. Market Revenue and Forecast, by Sales Channel (2017-2030)
14.3.13.6. Market Revenue and Forecast, by Distribution Channel (2017-2030)
14.4. MEA
14.4.1. Market Revenue and Forecast, by Type (2017-2030)
14.4.2. Market Revenue and Forecast, by Drug (2017-2030)
14.4.3. Market Revenue and Forecast, by Product (2017-2030)
14.4.4. Market Revenue and Forecast, by Dosage Form (2017-2030)
14.4.5. Market Revenue and Forecast, by Sales Channel (2017-2030)
14.4.6. Market Revenue and Forecast, by Distribution Channel (2017-2030)
14.4.7. GCC
14.4.7.1. Market Revenue and Forecast, by Type (2017-2030)
14.4.7.2. Market Revenue and Forecast, by Drug (2017-2030)
14.4.7.3. Market Revenue and Forecast, by Product (2017-2030)
14.4.7.4. Market Revenue and Forecast, by Dosage Form (2017-2030)
14.4.8. Market Revenue and Forecast, by Sales Channel (2017-2030)
14.4.9. Market Revenue and Forecast, by Distribution Channel (2017-2030)
14.4.10. North Africa
14.4.10.1. Market Revenue and Forecast, by Type (2017-2030)
14.4.10.2. Market Revenue and Forecast, by Drug (2017-2030)
14.4.10.3. Market Revenue and Forecast, by Product (2017-2030)
14.4.10.4. Market Revenue and Forecast, by Dosage Form (2017-2030)
14.4.11. Market Revenue and Forecast, by Sales Channel (2017-2030)
14.4.12. Market Revenue and Forecast, by Distribution Channel (2017-2030)
14.4.13. South Africa
14.4.13.1. Market Revenue and Forecast, by Type (2017-2030)
14.4.13.2. Market Revenue and Forecast, by Drug (2017-2030)
14.4.13.3. Market Revenue and Forecast, by Product (2017-2030)
14.4.13.4. Market Revenue and Forecast, by Dosage Form (2017-2030)
14.4.13.5. Market Revenue and Forecast, by Sales Channel (2017-2030)
14.4.13.6. Market Revenue and Forecast, by Distribution Channel (2017-2030)
14.4.14. Rest of MEA
14.4.14.1. Market Revenue and Forecast, by Type (2017-2030)
14.4.14.2. Market Revenue and Forecast, by Drug (2017-2030)
14.4.14.3. Market Revenue and Forecast, by Product (2017-2030)
14.4.14.4. Market Revenue and Forecast, by Dosage Form (2017-2030)
14.4.14.5. Market Revenue and Forecast, by Sales Channel (2017-2030)
14.4.14.6. Market Revenue and Forecast, by Distribution Channel (2017-2030)
14.5. Latin America
14.5.1. Market Revenue and Forecast, by Type (2017-2030)
14.5.2. Market Revenue and Forecast, by Drug (2017-2030)
14.5.3. Market Revenue and Forecast, by Product (2017-2030)
14.5.4. Market Revenue and Forecast, by Dosage Form (2017-2030)
14.5.5. Market Revenue and Forecast, by Sales Channel (2017-2030)
14.5.6. Market Revenue and Forecast, by Distribution Channel (2017-2030)
14.5.7. Brazil
14.5.7.1. Market Revenue and Forecast, by Type (2017-2030)
14.5.7.2. Market Revenue and Forecast, by Drug (2017-2030)
14.5.7.3. Market Revenue and Forecast, by Product (2017-2030)
14.5.7.4. Market Revenue and Forecast, by Dosage Form (2017-2030)
14.5.8. Market Revenue and Forecast, by Sales Channel (2017-2030)
14.5.8.1. Market Revenue and Forecast, by Distribution Channel (2017-2030)
14.5.9. Rest of LATAM
14.5.9.1. Market Revenue and Forecast, by Type (2017-2030)
14.5.9.2. Market Revenue and Forecast, by Drug (2017-2030)
14.5.9.3. Market Revenue and Forecast, by Product (2017-2030)
14.5.9.4. Market Revenue and Forecast, by Dosage Form (2017-2030)
14.5.9.5. Market Revenue and Forecast, by Sales Channel (2017-2030)
14.5.9.6. Market Revenue and Forecast, by Distribution Channel (2017-2030)
Chapter 15. Company Profiles
15.1. Novartis AG
15.1.1. Company Overview
15.1.2. Product Offerings
15.1.3. Financial Performance
15.1.4. Recent Initiatives
15.2. AbbVie, Inc.
15.2.1. Company Overview
15.2.2. Product Offerings
15.2.3. Financial Performance
15.2.4. Recent Initiatives
15.3. Sun Pharmaceutical Industries Ltd.
15.3.1. Company Overview
15.3.2. Product Offerings
15.3.3. Financial Performance
15.3.4. Recent Initiatives
15.4. Santen Pharmaceutical Co., Ltd.
15.4.1. Company Overview
15.4.2. Product Offerings
15.4.3. Financial Performance
15.4.4. Recent Initiatives
15.5. AFT Pharmaceuticals
15.5.1. Company Overview
15.5.2. Product Offerings
15.5.3. Financial Performance
15.5.4. Recent Initiatives
15.6. Johnson & Johnson Services, Inc.
15.6.1. Company Overview
15.6.2. Product Offerings
15.6.3. Financial Performance
15.6.4. Recent Initiatives
15.7. Otsuka Pharmaceutical Co., Ltd.
15.7.1. Company Overview
15.7.2. Product Offerings
15.7.3. Financial Performance
15.7.4. Recent Initiatives
15.8. OASIS Medical
15.8.1. Company Overview
15.8.2. Product Offerings
15.8.3. Financial Performance
15.8.4. Recent Initiatives
15.9. Oyster Point Pharma, Inc.
15.9.1. Company Overview
15.9.2. Product Offerings
15.9.3. Financial Performance
15.9.4. Recent Initiatives
15.10. Bausch & Lomb
15.10.1. Company Overview
15.10.2. Product Offerings
15.10.3. Financial Performance
15.10.4. Recent Initiatives
Chapter 16. Research Methodology
16.1. Primary Research
16.2. Secondary Research
16.3. Assumptions
Chapter 17. Appendix
17.1. About Us
17.2. Glossary of Terms
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers